Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Mary-Elizabeth Patti MD, FACP

Mary-Elizabeth Patti MD, FACP

Investigator, Adult Endocrinologist, and Director, Hypoglycemia Clinic, Joslin Diabetes Center; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Dr. Patti is a physician-scientist, serving as Principal Investigator at Joslin Diabetes Center, Director of the Hypoglycemia Clinic, Co-Director of the Molecular Phenotyping Core, and Associate Professor of Medicine at Harvard Medical School.  Dr. Patti’s NIH-funded lab focuses on identification of molecular/epigenetic mechanisms by which nutritional exposures during early life increase diabetes risk in subsequent generations.  Translational studies are focused on mechanisms contributing to diabetes resolution and hypoglycemia after bariatric surgery.  Dr. Patti received her MD from Jefferson Medical College magna cum laude, with internal medicine residency at University of Pittsburgh, and endocrinology fellowship at Harvard. 

Disclosures

Dr. Patti gratefully acknowledges support from NIH R01 DK121995, R01 DK106193, U01 DK114156, P30 DK036836 (DRC, Joslin Diabetes Center) and the Chan Zuckerberg Foundation.

Dr. Patti has been a coinvestigator on an NIH R44 grant together with Xeris Pharmaceuticals. She has consulted for Eiger Pharmaceuticals, has received investigator-initiated grant support from Janssen Pharmaceuticals, Medimmune, Sanofi, Astra-Zeneca, Jenesis, and Nuclea, has been a site investigator for XOMA and Xeris, and acknowledges clinical trial research trial product support from Ethicon, Covidien, NovoNordisk, Nestle, and Dexcom within the past 5 years – all unrelated to the present study. Dr. Patti has submitted a patent application regarding plasma proteins contributing to hypoglycemia and pump therapies for hypoglycemia. No other relationships or activities occurred that could appear to have influenced the submitted work.